PubMed · 6333157
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
W K Hoddick, B E Demas, A A Moss. 1984. CT-guided percutaneous bowel loopogram.. https://doi.org/10.2214/ajr.143.5.1098
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Acetylcholine is a neurotransmitter that has been implicated in the pathophysiology of major depression. This is supported by the enhanced growth hormone (GH) release in response to pyridostigmine (PYD) challenge in depressed subjects relative to healthy comparison subjects. The aim of this study is to examine the specificity of the PYD/GH challenge in the diagnosis of depression. Pyridostigmine 120 mg orally, was administered to a total of 116 physically healthy subjects. Growth hormone responses were studied in 38 patients with (DSM-III-R) major depression, 13 subjects with panic disorder, 9 subjects with schizophrenia, 10 recently detoxified alcoholics, and a comparison group of 46 healthy volunteers. Mean delta GH (the difference between basal and maximal GH following PYD) was significantly greater than comparison subjects in patients with major depression. Responses observed in patients with schizophrenia and alcohol dependence syndrome did not differ from the comparison group. Those patients with panic disorder and a high Hamilton depression score had an enhanced delta GH. The sensitivity of the PYD/GH test was 63% for major depression. These results indicate that the PYD/GH test may help distinguish depression from schizophrenia, alcohol-dependence syndrome, or panic disorder with a low Hamilton depression score.
Explore the source record for details and available documents.
Perinatal exposure of rodents to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has been shown to result in thymic atrophy and cell-mediated immune suppression at lower doses than are required to produce those effects following adult exposure. This study was designed to examine the effects that in utero TCDD exposure has on thymocyte development in the rat. Timed-bred pregnant F344 rats were given 0, 1.0, or 3.0 mcg TCDD/kg body weight by gavage on gestational day 14 (GD14). On GD19 or GD22/postnatal day one (PD1), the dams were euthanized, and the dams and their offspring were examined for organ weight and thymus phenotypic alterations. GD19 fetuses from the 3.0 mcg TCDD/kg maternal exposure group exhibited decreases in relative thymus weight and thymic cellularity. There were a decreased percentage of CD3-/CD4+ CD8+ thymocytes and an increased percentage of CD3-/CD4-CD8+ thymocytes in these fetuses, but there were no alterations in the CD3+ subsets. No effects were seen in the GD19 fetuses from the 1.0 mcg TCDD/kg dosage group. In the TCDD-exposed GD22/PD1 offspring thymic atrophy was no longer present, but there was an increase in the relative liver weight. In addition, there were decreased percentages of CD3-/CD4-CD8-, CD3+/CD4-CD8-, and CD3+/CD4+CD8+ thymocytes and an increased percentage of CD3+/CD4-CD8+ thymocytes. The CD3+/CD4-CD8- and CD3+/CD4-CD8+ cell populations were the most sensitive, with changes appearing at both 1.0 and 3.0 mcg TCDD/kg maternal exposures. The TCDD-exposed GD19 dams exhibited an increased relative liver weight, a decreased relative thymus weight, and alterations in thymic CD3+ populations. Three days later the relative organ weights had recovered in the dams, but the phenotypic alterations were seen in CD3- as well as CD3+ thymocyte subsets. These results indicate that the developing rat fetal thymus is susceptible to the effects of TCDD. In addition, pregnant rats and their offspring showed similar alterations in thymocytic phenotypes.